Oncoviruses and innate immunity

Afficher tout

Publications

The Human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.
Hasan UA, Zannetti C, Parroche P, Goutagny N, Malfroy M, Roblot G, Carreira C, Hussain I, Müller M, Taylor-Papadimitriou J, Picard D, Sylla BS, Trinchieri G, Medzhitov R, Tommasino M.
J Exp Med. 2013 Jul 1;210(7):1369-87. doi: 10.1084/jem.20122394.

MyD88 and its divergent toll in carcinogenesis.
Salcedo R, Cataisson C, Hasan U, Yuspa SH, Trinchieri G.
Trends Immunol. 2013 May 6. doi:pii: S1471-4906(13)00055-0. 10.1016/j.it.2013.03.008.

Targeting pattern recognition receptors in cancer immunotherapy.
Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C.
Target Oncol. 2012 Mar;7(1):29-54. doi: 10.1007/s11523-012-0213-1.

Human papillomavirus type 16 E6 inhibits p21(WAF1) transcription independently of p53 by inactivating p150(Sal2).
Parroche P, Touka M, Mansour M, Bouvard V, Thépot A, Accardi R, Carreira C, Roblot GG, Sylla BS, Hasan U*, Tommasino M*.
Virology. 2011 Sep 1;417(2):443-8. doi: 10.1016/j.virol.2011.05.016. *co-last authors

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.
Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trépo C, Hasan U, Chemin I.
PLoS One. 2011;6(10):e26315. doi: 10.1371/journal.pone.0026315.

NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis.
Hussain I, Fathallah I, Accardi R, Yue J, Saidj D, Shukla R, Hasan U, Gheit T, Niu Y, Tommasino M, Sylla BS.
J Virol. 2011 Sep;85(17):9013-22. doi: 10.1128/JVI.00002-11.

EBV latent membrane protein 1 is a negative regulator of TLR9.
Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, Manet E, Tommasino M, Sylla BS, Hasan UA.
J Immunol. 2010 Dec 1;185(11):6439-47. doi: 10.4049/jimmunol.0903459.

Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.
Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D.
Trends Immunol. 2010 Oct;31(10):391-7. doi: 10.1016/j.it.2010.07.004.

C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.
Zannetti C, Bonnay F, Takeshita F, Parroche P, Ménétrier-Caux C, Tommasino M, Hasan UA.
J Biol Chem. 2010 Nov 5;285(45):34773-80. doi: 10.1074/jbc.M110.133884.

The biological properties of E6 and E7 oncoproteins from human papillomaviruses.
Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M.
Virus Genes. 2010 Feb;40(1):1-13. doi: 10.1007/s11262-009-0412-8.

Double stranded RNA tricks melanoma cells into committing suicide.
Goldszmid RS, Hasan UA, Trinchieri G.
Pigment Cell Melanoma Res. 2009 Dec;22(6):705-6. doi: 10.1111/j.1755-148X.2009.00631.x.

Multifocal tumors of the testis.
Cambio JC, Hasan U, Hussain A.
Med Health R I. 2009 Jun;92(6):212-3.

Patents

  • Hasan U.A, Dollet S, Vlach J US Patent No: 7,498,409
  • Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
    Hasan U.A,Dollet S, Vlach J. SELECTIVE AGONISTS OF HUMAN TOLL-LIKE RECEPTOR 8. SF6266. 2005.